Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 2
1984 2
1985 28
1986 31
1987 70
1988 96
1989 116
1990 141
1991 175
1992 240
1993 242
1994 294
1995 329
1996 337
1997 402
1998 376
1999 377
2000 366
2001 436
2002 437
2003 434
2004 479
2005 510
2006 555
2007 554
2008 556
2009 648
2010 652
2011 660
2012 707
2013 715
2014 726
2015 765
2016 788
2017 785
2018 765
2019 776
2020 927
2021 965
2022 1004
2023 923
2024 270

Text availability

Article attribute

Article type

Publication date

Search Results

17,900 results

Results by year

Filters applied: . Clear all
Page 1
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.
Geyer CE, Sikov WM, Huober J, Rugo HS, Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo JP, Metzger O, Dunbar M, Symmans WF, Rastogi P, Sohn JH, Young R, Wright GS, Harkness C, McIntyre K, Yardley D, Loibl S. Geyer CE, et al. Ann Oncol. 2022 Apr;33(4):384-394. doi: 10.1016/j.annonc.2022.01.009. Epub 2022 Jan 31. Ann Oncol. 2022. PMID: 35093516 Free article. Clinical Trial.
PATIENTS AND METHODS: Women with untreated stage II-III TNBC were randomized (2 : 1 : 1) to paclitaxel (weekly for 12 doses) plus: (i) carboplatin (every 3 weeks for four cycles) plus veliparib (twice daily); (ii) carboplatin plus veliparib placebo; or (iii) carb
PATIENTS AND METHODS: Women with untreated stage II-III TNBC were randomized (2 : 1 : 1) to paclitaxel (weekly for 12 doses) plus: (i) ca
Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
Griesinger F, Korol EE, Kayaniyil S, Varol N, Ebner T, Goring SM. Griesinger F, et al. Lung Cancer. 2019 Sep;135:196-204. doi: 10.1016/j.lungcan.2019.07.010. Epub 2019 Jul 13. Lung Cancer. 2019. PMID: 31446995 Free article.
Differences in drug-related toxicities were observed between carboplatin- and cisplatin-based chemotherapy for thrombocytopenia, anaemia, neurotoxicity, and the risk of nausea/vomiting. Three RCTs comparing HRQoL between carboplatin- and cisplatin-based chemotherapy …
Differences in drug-related toxicities were observed between carboplatin- and cisplatin-based chemotherapy for thrombocytopenia, anae …
Thermoresponsive carboplatin-releasing prodrugs.
McAdam AD, Batchelor LK, Romano-deGea J, Vasilyev D, Dyson PJ. McAdam AD, et al. J Inorg Biochem. 2024 May;254:112505. doi: 10.1016/j.jinorgbio.2024.112505. Epub 2024 Feb 15. J Inorg Biochem. 2024. PMID: 38377623 Free article.
Perfluorinated chains of varying lengths were installed on carboplatin, a clinically approved drug, leading to the successful synthesis of a series of mono- and di- substituted platinum(IV) carboplatin prodrugs. Some of these complexes display relevant thermosensiti …
Perfluorinated chains of varying lengths were installed on carboplatin, a clinically approved drug, leading to the successful synthes …
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E; AGO-OVAR; NCIC CTG; EORTC GCG. Pfisterer J, et al. J Clin Oncol. 2006 Oct 10;24(29):4699-707. doi: 10.1200/JCO.2006.06.0913. Epub 2006 Sep 11. J Clin Oncol. 2006. PMID: 16966687 Clinical Trial.
RESULTS: Three hundred fifty-six patients (178 gemcitabine plus carboplatin; 178 carboplatin) were randomly assigned. Patients received a median of six cycles in both arms. ...Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin a …
RESULTS: Three hundred fifty-six patients (178 gemcitabine plus carboplatin; 178 carboplatin) were randomly assigned. Patients …
Carboplatin-associated Cranial Neuropathy.
Stevens SM, McClelland CM, Trusheim JE, Lee MS. Stevens SM, et al. Neuroophthalmology. 2018 Jan 26;42(5):302-305. doi: 10.1080/01658107.2017.1419367. eCollection 2018 Oct. Neuroophthalmology. 2018. PMID: 30258477 Free PMC article.
Carboplatin is a platinum-based chemotherapeutic agent used for the treatment of many solid tumors. ...We describe a case of persistent third and fourth nerve palsies after systemic administration of intra-arterial carboplatin for glioblastoma multiforme. Neither ne
Carboplatin is a platinum-based chemotherapeutic agent used for the treatment of many solid tumors. ...We describe a case of persiste
Hypersensitivity to Carboplatin in Children with Malignancy.
Ruggiero A, Rizzo D, Catalano M, Attinà G, Riccardi R. Ruggiero A, et al. Front Pharmacol. 2017 Apr 12;8:201. doi: 10.3389/fphar.2017.00201. eCollection 2017. Front Pharmacol. 2017. PMID: 28446876 Free PMC article. Review.
Purpose: Carboplatin-based regimens have proven efficacy in children with cancer. ...Results: Carboplatin HSRs present with mild/moderate to severe clinical patterns. ...
Purpose: Carboplatin-based regimens have proven efficacy in children with cancer. ...Results: Carboplatin HSRs present with mi …
The Affinity of Carboplatin to B-Vitamins and Nucleobases.
Szefler B, Czeleń P, Krawczyk P. Szefler B, et al. Int J Mol Sci. 2021 Mar 31;22(7):3634. doi: 10.3390/ijms22073634. Int J Mol Sci. 2021. PMID: 33807309 Free PMC article.
The anticancer activity of carboplatin arises from interacting with DNA and inducing programmed cell death. However, such interactions may occur with other chemical compounds, such as vitamins containing aromatic rings with lone-pair orbitals, which reduces the anti-cancer …
The anticancer activity of carboplatin arises from interacting with DNA and inducing programmed cell death. However, such interaction …
[Carboplatin in cancer of the ovary].
Pujade-Lauraine E, Guastalla JP, Vincent P. Pujade-Lauraine E, et al. Bull Cancer. 2000 Aug;87 Spec No:40-7. Bull Cancer. 2000. PMID: 11082722 Free article. Review. French.
The sample of more than 2,000 patients enrolled in randomised trials and 2 meta-analyses were largely sufficient to prove that carboplatin and cisplatin are equally effective. Carboplatin dose adaptation according to renal function and AUC decreases drug induced thr …
The sample of more than 2,000 patients enrolled in randomised trials and 2 meta-analyses were largely sufficient to prove that carboplati
Concomitant Chemoradiation Therapy with Gold Nanoparticles and Platinum Drugs Co-Encapsulated in Liposomes.
Charest G, Tippayamontri T, Shi M, Wehbe M, Anantha M, Bally M, Sanche L. Charest G, et al. Int J Mol Sci. 2020 Jul 9;21(14):4848. doi: 10.3390/ijms21144848. Int J Mol Sci. 2020. PMID: 32659905 Free PMC article.
Radiosensitization by GNPs alone or carboplatin alone was observed only at high concentrations of these compounds. Furthermore, low doses of carboplatin alone or a combination of carboplatin and GNPs did not engender radiosensitization. ...
Radiosensitization by GNPs alone or carboplatin alone was observed only at high concentrations of these compounds. Furthermore, low d …
Carboplatin hypersensitivity in relapsed ovarian carcinoma: A therapeutic challenge.
Pandey A, Bhosale B, Pandita V, Singh A, Ghosh J, Ghosh J, Bajpai J. Pandey A, et al. Indian J Med Paediatr Oncol. 2014 Jan;35(1):17-20. doi: 10.4103/0971-5851.133705. Indian J Med Paediatr Oncol. 2014. PMID: 25006278 Free PMC article. Review.
Carboplatin with its better toxicity profile has replaced cisplatin as the first line drug. However, increase in incidence of carboplatin hypersensitivity is alarming. Severity of carboplatin hypersensitivity varies from a mild rash to life-threatening reacti
Carboplatin with its better toxicity profile has replaced cisplatin as the first line drug. However, increase in incidence of carb
17,900 results
You have reached the last available page of results. Please see the User Guide for more information.